High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome

Hashida, Noriyasu; Ohguro, Nobuyuki; Yamazaki, Noboru; Arakawa, Yukio; Oiki, Eiji; Mashimo, Hisashi; Kurokawa, Nobuo; Tano, Yasuo

doi:10.1016/j.exer.2007.10.004

Cited by 53 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pegylated liposomal doxorubicin has shown substantial efficacy in breast cancer treatment as monotherapy and in combination with other chemotherapeutics. Liposomes with Sialyl Lewis X (SLX) proved to work as imaging reagent and drug delivery agent for fluorescent markers, proteins and genes [21,22]. Some liposomes were produced by encapsulating perfluorocarbon nanoparticle to be utilized as an imaging contrast agent.…”

Section: Platforms For Anticancer Drug Deliverymentioning

confidence: 99%

Impact of Nanoparticles on Cancer Therapy

Alkhatib¹,

Albishi²,

Mahassni³

2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

The tremendous contribution of nanotechnology to the treatment and diagnosis of medical diseases has recently attracted the attention of anticancer researchers. Most of the new nanoparticle carriers have improved drug bioavailability and reduced the cytotoxic effects of the drugs. This article presents an overview of the recent advances of nanotechnology in cancer therapy. It covers the mechanisms of cellular uptake for anticancer drugs delivered in nanoscale systems by either active or passive targeting. The various nanoscale systems employed in drug delivery and their immense potential in diagnosis andimaging of cancerous tumors are also addressed.

show abstract

Section: Platforms For Anticancer Drug Deliverymentioning

confidence: 99%

Impact of Nanoparticles on Cancer Therapy

Alkhatib¹,

Albishi²,

Mahassni³

2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…However, intravenously administered nanoparticles achieve ocular targeting from the endothelial side and sustained release in ocular inflammation although more than 95 per cent of the nanoparticles are trapped in the liver and spleen. As a second approach to endothelial delivery to the inflamed eye the work of Hashida et al (2008) should be mentioned. Novel SLX-conjugated liposomes were loaded with dexamethasone and were injected to EAU mice.…”

Section: Uveitismentioning

confidence: 99%

Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases

Ulbrich

Lamprecht

2009

J. R. Soc. Interface.

155

View full text Add to dashboard Cite

Limitations in therapy induced by adverse effects due to unselective drug availability and therefore the use of potentially too high doses are a common problem. One prominent example for this dilemma are inflammatory diseases. Colloidal carriers allow one to improve delivery of drugs to the site of action and appear promising to overcome this general therapeutic drawback. Specific uptake of nanoparticles by immune-related cells in inflamed barriers offers selective drug targeting to the inflamed tissue. Here we focus on nanocarrier-based drug delivery strategies for the treatment of common inflammatory disorders like rheumatoid arthritis, multiple sclerosis, uveitis or inflammatory bowel disease.

show abstract

“…The feasibility of a glycoliposome conjugated with SLX for drug transfer into activated endothelial cells has been demonstrated in vitro (Stahn et al, 2001). A novel type of SLX-liposome was developed, on which the SLX tetrasaccharides were bound via human serum albumins, and tris (hydroxymethyl) aminomethane (Tris) was coated for hydrophilization as a "stealth liposome" (Hirai et al, 2007;Hashida et al, 2008). The efficient accumulation of the SLX-liposome to inflamed and tumor regions was examined with in vivo models treated with Cy5.5 encapsulating SLX-liposome using an in vivo fluorescent imaging system (Hirai et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Transvascular accumulation of Sialyl Lewis X conjugated liposome in inflamed joints of collagen antibody-induced arthritic (CAIA) mice

Minaguchi

Oohashi

Inagawa

et al. 2008

Arch. Histol. Cytol.

View full text Add to dashboard Cite

Summary. The aim of the current study was to investigate the specific accumulation of the Sialyl Lewis X (SLX) liposome in inflammation in the collagen-antibody induced arthritic (CAIA) model mice. The SLX-liposome encapsulating fluorescent substance (Cy5.5 or Cy3) was prepared for this study. The SLX-liposome was administered intravenously via the mouse caudal vein. After 1 to 24 h, the accumulation of SLX-liposome was observed using in vivo fluorescent imaging equipment (eXplore Optix), or the knee joints were removed for histological analysis. The in vivo fluorescent imaging showed that the signal was confined to the inflammatory site in the CAIA mice in an inflammatory dependent manner. The signal intensity was stronger at 24 h than at 1 h after injection. In the histological sections, the fl uorescent signals were detected in the periarticular softtissue, especially in the hyperplastic synovium, including a pannus invasion with inflammatory cells in the CAIA. Intense signals were observed in vessel-like structures 1 h after injection; these were co-labeled with the vascular endothelial cell marker (CD31) and E-selectin, a ligand of the SLX-liposome expressed on activated endothelial cells. The diffused signals from the vessels increased time-dependently at 6 to 24 h after injection. This is the fi rst report to examine the exact localization of the SLXliposome by encapsulated fluorescence in hyperplastic synovial tissue of CAIA mice. These results suggest the feasibility and potential use of SLX-liposome as a vehicle for the active targeting of drug delivery to infl ammatory tissue.

show abstract

High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome

Cited by 53 publications

References 22 publications

Impact of Nanoparticles on Cancer Therapy

Impact of Nanoparticles on Cancer Therapy

Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases

Transvascular accumulation of Sialyl Lewis X conjugated liposome in inflamed joints of collagen antibody-induced arthritic (CAIA) mice

Contact Info

Product

Resources

About